Document:

exv10w4

 

[***] Indicates
text has been omitted from this Exhibit pursuant to a confidential treatment
request and has been filed separately with the Securities and Exchange Commission.

Exhibit 10.4

	 	 	 
	 

	 	2020.LICI.001.B
	 

	 	California Institute of Technology

SECOND AMENDED AND RESTATED LICENSE AGREEMENT

     This SECOND AMENDED AND RESTATED LICENSE AGREEMENT
(“Agreement”), effective May 1, 2000 (the “Effective Date”) with a second restatement
date as of May 1, 2004 (the “Second Restatement Date”), between California Institute
Of Technology, 1200 East California Boulevard, Pasadena, California 91125
(“Caltech”) and Fluidigm Corporation, 7100 Shoreline Court, South San Francisco,
California 94080 (formerly Mycometrix Corporation) (“Licensee”).

     Whereas, Caltech has been engaged in basic research in the field of microfluidics;

     Whereas, that research led to the United States patents, patent applications and
other inventions listed in Exhibit A, which are owned, solely or jointly, by Caltech;

     Whereas, Licensee is desirous of obtaining, and Caltech wishes to grant to
Licensee, an exclusive license (or the maximum rights Caltech can grant) to the Licensed
Patents (as defined in Section 1.5) and Improvements thereof in the Field (as defined in
Sections 1.4 and 1.3, respectively) and an exclusive license to the Technology (as
defined in Section 1.9);

     Whereas, the Caltech and Licensee have entered into a prior License
Agreement made as of May 1, 2000, and an Amended and Restated License Agreement made as
of June 1, 2002, which the parties now wish to further amend and restate as set forth
herein.

     Now, Therefore, the parties agree as follows:

 

 

ARTICLE 1

DEFINITIONS

     1.1 
 “Affiliate” shall mean, with respect to Licensee, any entity which controls, is
controlled by or is under common control with Licensee. An entity shall be regarded as in control
of another entity for purposes of this definition if it owns or
controls fifty percent (50%) or
more of the shares of the subject entity entitled to vote in the election of directors (or, in the
case of an entity that is not a corporation, for the election of the corresponding managing
authority). “Affiliate” shall mean, with respect to Caltech, any research entity which is operated
or managed as a facility under Caltech.

     1.2  
“Deductible Expenses” means (i) all trade, cash and quantity credits, discounts, refunds
or government rebates; (ii) amounts for claims, allowances or credits for returns, retroactive
price reductions, or chargebacks; (iii) packaging, handling fees and prepaid freight, sales taxes,
duties and other governmental charges (including value added tax); and (iv) provisions for
uncollectible accounts determined in accordance with reasonable accounting practices, consistently
applied to all products of the selling party. For the removal of doubt, Net Sales shall not
include sales by Licensee to its Affiliates for resale, provided that if Licensee sells a Licensed
Product to an Affiliate for resale, Net Sales shall include the amounts invoiced by such Affiliate
to third parties on the resale of such Licensed Product. In the event that Licensee grants a
sublicense hereunder, and receives payments based upon the Sublicensee’s sales of Licensed
Products, Licensee may upon notice to Caltech modify this definition of “Net Sales” for purposes
of calculating royalties payable to Caltech on such Sublicensee’s sales to be the same as the
definition of “Net Sales” on which such royalties to Licensee are calculated.

     1.3  
“Field” means [***] 

- 2 -

 

[***]

     1.4 “Improvements” shall mean all Caltech rights (whether or not Caltech has sole or joint
rights) in any improvement or invention conceived and reduced to practice or otherwise developed
in or arising from research in the Field as conducted by
Dr. Stephen Quake, researchers of the Quake laboratory, or in
collaboration with members of the Frances Arnold or Axel Scherer
laboratories, whether invented solely by Caltech researchers or
jointly with (i) Licensee or (ii) other researchers without
an obligation of assignment to Caltech.

     1.5 “Licensed Patents” means the patent applications listed in Exhibit A hereto; any patents
issuing on such patent applications, all divisionals, continuations, continuations-in-part,
patents of addition, substitutions, registrations, reissues, reexaminations or extensions of any
kind with respect to any of the existing patents and any foreign counterparts of such patent
applications and patents, and Improvements.

     1.6 “Licensed Product” means products covered by a Valid Claim of a Licensed Patent in the
country in which such product is sold or products in which the Technology is utilized.

     1.7 “Net Sales” means the total amount invoiced to third parties on sales of Licensed
Products for which royalties are due under Article 4 below, less, to the extent allocable to such
invoiced amounts, Deductible Expenses.

     1.8 “Sublicensee” shall mean any non-Affiliate third party to whom Licensee has granted the
right under the Licensed Patents and Technology to manufacture and sell Licensed Products, with
respect to Licensed Products made and sold by such third party.

- 3 -

 

     1.9 “Technology” means all proprietary information, know-how, procedures, methods, prototypes,
designs, technical data, reports, and data owned by Caltech that are
necessary or useful in the development of products in the Field covered by any issued patent or
pending patent application within the Licensed Patents, and which relate to such products.

     1.10 “Valid Claim” means a claim of an issued and unexpired patent or a claim of a pending
patent application within the Licensed Patents which has not been held unpatentable, invalid or
unenforceable by a court or other government agency of competent jurisdiction and
has not been admitted to be invalid or unenforceable through reissue, re-examination, disclaimer
or otherwise; provided, however, that if the holding of such court or agency is later reversed by
a court or agency with overriding authority, the claim shall be reinstated as a Valid Claim with
respect to Net Sales made after the date of such reversal. Notwithstanding the foregoing
provisions of this Section 1.10, if a claim of a pending patent application within the Licensed
Patents has not issued as a claim of an issued patent within the Licensed Patents, within five (5)
years after the filing date from which such claim takes priority, such pending claim shall not be
a Valid Claim for purposes of this Agreement.

ARTICLE 2

PATENT LICENSE GRANT

     2.1 Caltech hereby grants to Licensee an exclusive, royalty-bearing, worldwide license, with
the right to grant and authorize sublicenses, under the Licensed Patents and Technology to make,
have made, use, import, offer for sale and sell Licensed Products, practice any method or
procedure and otherwise exploit the Licensed Patents and Technology.

     2.2 These licenses are subject to: (a) the reservation of Caltech’s right to make, have made,
and use Licensed Products for noncommercial educational and research purposes, but not for sale or
other distribution to third parties; and (b) the rights of the U.S. Government under Title 35,
United States Code, Section 200 et seq., including but not limited to the grant to the U.S.
government of a nonexclusive, nontransferrable, irrevocable, paid-up license to practice or have
practiced any invention conceived or first actually reduced to practice in the performance of work
for or on behalf of the U.S. Government throughout the world. These licenses are not

- 4 -

 

transferable by Licensee except as provided in Section 16.4, but Licensee shall have the right to
grant non-exclusive or exclusive sublicenses hereunder, provided that:

          (a) License shall include all its sublicensing income in Licensee’s reports to
Caltech, as provided in Section 9.2, and Licensee shall pay royalties thereon to Caltech
pursuant
to Section 4.2 and 4.4;

          (b) Licensee shall furnish Caltech within thirty (30) days of the execution thereof, a true
and complete copy of each sublicense and any changes or additions thereto;

          (c) License may grant sublicenses of no greater scope than the license granted under Section
2.1; and

     Each sublicense granted by Licensee shall include provisions similar in all material
respects to those of Articles 6, 12, 15, 16 and Section 2.2.

ARTICLE 3

IMPROVEMENTS

     3.1 The parties acknowledge that Exhibit A includes all Improvements disclosed by Caltech to
Licensee between May 1, 2000 and the Second Restatement Date, and elected by Licensee as of the
Second Restatement Date. Caltech shall notify Licensee in writing of Improvements made after the
Second Restatement Date and during the term of the Agreement. Upon receipt of an invention
disclosure constituting an Improvement, Licensee can elect to add such Improvement and any related
patent filings to Exhibit A hereof to be within the Licensed
Patents. Thereafter, Licensee shall
be responsible for patent prosecution and costs associated with such elected Improvement in
accordance with Article 11 herein, as well as to issue additional stock pursuant to Section 5.3.
No less than at each anniversary of the Second Restatement Date, Exhibit A shall be updated by the
parties to reflect the inclusion of all Improvements so elected, as well as updates on all
Licensed Patents.

- 5 -

 

ARTICLE 4

ROYALTIES

     4.1 With respect to Licensed Products manufactured or sold by Licensee in a country in which
such manufacture or sale is covered by a Valid Claim of a Licensed Patent, Licensee agrees to pay
Caltech [***] of Net Sales of such Licensed Products wherein the Licensed
Products are instruments or apparatus directly used for the reading and/or analysis of data from
other Licensed Products, including microfluidic chips that are
Licensed Products, and [***] of Net Sales of Licensed Products by Licensee for all such other Licensed Products,
including microfluidic chips that are Licensed Products, Royalties due under this Section 4.1 shall
be payable on a country-by-country and Licensed Product-by-Licensed Product basis until the
expiration of the last-to-expire issued Valid Claim covering such Licensed Product in such country.

     4.2 With respect to Licensed Products manufactured or sold by Sublicensees in a country in
which such manufacture or sale is covered by a Valid Claim of a Licensed Patent, Licensee agrees to
pay Caltech [***] of the revenues received by Licensee from Sublicensees’ Net Sales
of such Licensed Products wherein the Licensed Products are instruments or apparatus directly used
for the reading and/or analysis of data from other Licensed Products, including microfluidic chips
that are Licensed Products, and [***] of the revenues received by Licensee from
Sublicensees’ Net Sales of Licensed Products for all such other Licensed Products, including
microfluidic chips that are Licensed Products. Royalties due under this Section 4.2 shall be
payable on a country-by-country and Licensed Product-by-Licensed Product basis until the expiration
of the last-to-expire issued Valid Claim covering such Licensed Product in such country.

     4.3 With respect to Licensed Products manufactured or sold by Licensee in a country in which
such manufacture or sale is not covered by Valid Claim of a Licensed Patent but the Technology is
utilized, Licensee agrees to pay Caltech [***] of Net
Sales of such Licensed Products by Licensee, wherein the Licensed Products are instruments or

- 6 -

 

apparatus directly used for the reading and/or analysis of data from other Licensed Products,
including microfluidic chips that are Licensed Products, and [***] of Net
Sales of Licensed Products by Licensee for all such other Licensed Products, including microfluidic
chips that are Licensed Products. Royalties due under this Section 4.3 shall be payable on a
country-by-country and Licensed Product-by-Licensed Product basis for a period of [***] years
from the Effective Date or the issuance of a U.S. patent that covers the Licensed Product,
whichever first occurs.

     4.4 With respect to Licensed Products manufactured or sold by Sublicensees in a country in
which such manufacture or sale is not covered by a Valid Claim of a Licensed Patent but the
Technology is utilized, Licensee agrees to pay Caltech [***] of the revenues received
by Licensee from Sublicensees’ Net Sales of such Licensed Products wherein the Licensed Products
are instruments or apparatus directly used for the reading and/or analysis of data from other
Licensed Products, including microfluidic chips that are Licensed Products, and [***] of the revenues received by Licensee from
Sublicensees’ Net Sales of
Licensed Products for all such other Licensed Products, including microfluidic chips that are
Licensed Products. Royalties due under this Section 4.4 shall be payable on a country-by-country
and Licensed Product-by-Licensed Product basis for a period of
[***] years from the Effective
Date or the issuance of a U.S. patent that covers the Licensed Product, whichever first occurs.

     4.5 Notwithstanding the above, it is understood and agreed that Caltech shall not be entitled
to any share of amounts received by Licensee for equity, debt, pilot studies, to support research
or development activities to be undertaken by Licensee, research and development or other
performance based milestones, the achievement by Licensee or Sublicensee of specified milestones
or benchmarks relating to the development of Licensed Products, the license or sublicense of any
intellectual property other than the Licensed Patents, reimbursement for patent or other expenses,
or with respect to products other than Licensed Products.

     4.6 In the event that a Licensed Product is sold in combination with one or more other
products or other items that are not Licensed Products, Net Sales for such combination products
will be reasonably calculated on a country-by-country and Licensed Product-by-Licensed

- 7 -

 

Product basis by Licensee by multiplying the Net Sales of that combination by a fraction equal to
the relative value of the combination attributable to the Licensed Product, in relation to the
relative value of the combination, as reasonably determined by Licensee in good faith. In addition,
in the event that a Licensed Product is not sold in combination with one or more other products or
other items that are not Licensed Products, but instead comprises multiple components, some of
which would constitute a Licensed Product if sold separately (each, a
“Licensed Component”), and
the others would not constitute a Licensed Product if sold separately, then Net Sales for such
Licensed Product will be calculated by multiplying the Net Sales of such Licensed Product by the
fraction A/B, where A is the gross selling price of the Licensed Component sold separately and B is
the gross selling price of such Licensed Product. If no such separate sales are made by Licensee,
its Affiliate or Sublicensee, Net Sales for such Licensed Product shall be calculated by
multiplying Net Sales of such Licensed Product by the fraction C/(C+D), where C is the fully
allocated cost of the Licensed Component and D is the fully allocated cost of the other components.

     4.7 Commencing on January 1, 2004, and continuing for each anniversary thereof during the term
of this Agreement, if Licensee has not paid, during the preceding calendar year, a minimum of [***] in royalties under Sections 4.1, 4.2, 4.3, and 4.4, Licensee agrees
to pay, on or before March 1 of that calendar year, an additional royalty for the prior calendar
year equal to the difference between [***] and any lower amount paid
under Sections 4.1, 4.2, 4.3, and 4.4 for the prior calendar year.

     4.8 In the event Licensee or Sublicensee becomes obligated to pay amounts to a third party
with respect to a Licensed Product for patent rights of a third party, Licensee may deduct
[***] of the amounts owing to such third party (prior to reductions) from the
amount owing to Caltech for such Licensed Product; provided, however, the amounts otherwise due to
Caltech shall not be so reduced by more than [***].

     4.9 For the purpose of determining royalties payable under this Agreement, any royalties or
other revenues Licensee receives from Sublicensees in currencies other than U.S. dollars and any
Net Sales denominated in currencies other than U.S. dollars shall be converted

- 8 -

 

into U.S. dollars according to Licensee’s reasonable standard internal conversion procedures,
including Licensee’s standard internal rates and conversion schedule.

     4.10 No more than one royalty payment shall be due with respect to a sale of a particular
Licensed Product. No multiple royalties shall be payable because any Licensed Product, or its
manufacture, sale or use is covered by more than one Valid Claim in a given country. No royalty
shall be payable under this Article 4 with respect to Licensed Products distributed for use in
research and/or development or as promotional samples or otherwise distributed without charge to
third parties.

     4.11 Any sublicenses granted by Licensee, including, without limitation, any nonexclusive
sublicenses, shall remain in effect in the event this license terminates pursuant to Article 12;
provided, the financial obligations of each Sublicensee to Caltech shall be limited to the amounts
Licensee shall be obligated to pay Caltech for the activities of such Sublicensee pursuant to this
Agreement.

     4.12 Royalties due under this Article 4 shall be payable on a country-by-country and Licensed
Product-by-Licensed Product basis until the expiration of the last-to-expire issued Valid Claim
covering such Licensed Product in such country, if the manufacture or sale of such Licensed Product
was at the time of the first commercial sale in such country covered
by a Valid Claim. Otherwise,
royalties due under this Article 4 shall be payable on a country-by-country and Licensed
Product-by-Licensed Product basis until [***] whichever first occurs.

     4.13 Notwithstanding the provisions of this Article 4, no royalty shall be payable to Caltech
with respect to any sales of Licensed Products to the U.S. Government on sales made solely to
permit the U.S. Government to practice or have practiced or have practiced or sue on its behalf
any invention or process covered by the Licensed Patents.

ARTICLE 5

LICENSEE EQUITY INTEREST

     5.1 In accordance with the License Agreement of May 1, 2000, Licensee issued to Caltech, in
consideration of Licensee’s receipt of the intangible property rights granted under

- 9 -

 

that License Agreement (which rights are carried forward herein), [***] shares of common stock of Licensee, pursuant to the terms of a reasonable and customary
stock issuance agreement. Further, it is acknowledged that, as partial consideration for entering
into the first Amended and Restated License Agreement of June 1, 2002, with the reformation of the
initial License Agreement of May 1, 2000 and the associated restatements and amendments (including,
but not limited to, an updated Exhibit A), Licensee issued to Caltech [***] shares of common stock of Licensee.

     5.2 Caltech agrees that, in the event of any underwritten or public offering of
securities of Licensee or a Affiliate, Caltech shall comply with and agree to any reasonable
restriction on the transfer of equity interest, or any part thereof, imposed by an underwriter, and
shall perform all acts and sign all necessary documents required with respect thereto.

     5.3 If Licensee wishes at its sole discretion to license hereunder any Improvements
disclosed by Caltech to Licensee during a twelve (12) month period beginning with June 1,
2003,
and for each anniversary thereafter (each twelve month period will be referred to as an
“Improvement Period”), Licensee shall notify Caltech in
writing accordingly within thirty (30) days after the end of
each Improvement Period. For the first two (2) Improvement Periods,
Licensee agrees to issue to Caltech, in consideration of Licensee’s election to receive
additional
intangible property rights to all Improvements disclosed to Licensee during an Improvement
Period, [***] shares of common stock of Licensee, pursuant to the terms of a
reasonable and customary stock issuance agreement. Thereafter, Licensee is hereby granted an
option by Caltech that Licensee can exercise during the final year of
the first two (2) Improvement Period on an annual basis on the same terms
and conditions. The consideration of this option was partially paid by the [***] shares granted by Licensee to Caltech as referenced in Section 5.1 of this Agreement. Further,
it
is acknowledged that pursuant to the initial License Agreement of May
1, 2000 and the first
Amended and Restated License Agreement of June 1, 2002, Licensee elected to receive
additional intangible property rights to Improvements disclosed to Licensee by Caltech during
May 1, 2000 through May 31, 2003, in consideration of the issuance to Caltech by Licensee of
[***] shares of common stock of Licensee (which represents the [***]
share grant under Section 5.1 above and [***] shares pursuant to the
parties’

- 10 -

 

Letter
Agreement dated June 19, 2003, paragraph #3), receipt of which
shares Caltech hereby acknowledges.

ARTICLE 6

DUE DILIGENCE

     6.1 Licensee agrees to use commercially reasonable efforts to introduce commercial Licensed
Product(s) as soon as practical, consistent with sound and reasonable business practices and
judgments. Licensee shall be deemed to have satisfied its obligations under this Section if
Licensee has an ongoing and active research program or marketing program, as appropriate, directed
toward production and use of one or more Licensed Products. Any efforts of Licensee’s Sublicensees
shall be considered efforts of Licensee for the sole purpose of determining Licensee’s compliance
with its obligation under this Section.

     6.2 After the first year from the Effective Date, Caltech shall have the right, no more often
than once each year, to require Licensee to report to Caltech in
writing on its progress in
introducing commercial Licensed Product(s) in the United States.

     6.3 If Licensee is not fulfilling its obligations under Section 6.1 with respect to the Field
and Caltech so notifies Licensee in writing, Caltech and Licensee shall negotiate in good faith
any additional efforts to be taken by Licensee. If the parties do not reach agreement within
ninety (90) days, the parties shall submit the issue to arbitration as provided in Article 14 to
determine whether any additional efforts shall be required of Licensee. If subsequent to the
conclusion of such arbitration proceedings Licensee then fails to make any required efforts, and
does not remedy that failure within sixty (60) days after further written notice to Licensee,
Caltech may convert the license granted in Section 2.1 to a nonexclusive license in any part of
the Field in which Licensee is not fulfilling its obligations under Section 6.1, and the royalties
payable under this Agreement shall be reduced by [***] for Licensed Products
in the Field sold under such a nonexclusive license.

- 11 -

 

ARTICLE 7

INFRINGEMENT BY THIRD PARTY

     7.1 Both Caltech and
Licensee agree to notify the other in writing should either party become
aware of infringement of the Licensed Patents. Licensee, upon notice to Caltech, shall have the
sole right to initiate an action against the infringer at Licensee’s expense, either in Licensee’s
name or in Caltech’s name if so required by law, Licensee shall have sole control of the action.

     7.2 If Licensee,
its Affiliate or Sublicensee, distributor or other customer is sued by a
third party charging infringement of patent rights that dominate a claim of the Licensed Patents
or that cover the development, manufacture, use, distribution or sale of a Licensed Product,
Licensee will promptly notify Caltech. As between the parties to this Agreement, Licensee shall
have sole control of the defense in any such action(s).

     7.3 If a declaratory
judgment action alleging invalidity unenforceability or
noninfringement of any of the Licensed Patents is brought against Licensee and/or Caltech,
Licensee may elect to have sole control of the action, and if
Licensee so elects it shall bear all the costs of the action. Licensee also may elect to undertake
and have sole control of the defense
of any interference, opposition or similar action with respect to the Licensed Patents providing
it bears all the costs of such action.

     7.4
In the event Licensee institutes a legal action pursuant to Section 7.1, within thirty
(30) days after receipt of notice of Licensee’s intent to institute such legal action,
Caltech shall
have the right to jointly prosecute such action and to fund up to
one-half (1⁄2) the costs of
such
action. Caltech shall fully cooperate with and supply all assistance reasonably requested by
Licensee, including by using commercially reasonable efforts to have its employees testify
when
requested and to make available relevant records, papers, information, samples, specimens,
and
the like. Licensee shall bear the reasonable expenses incurred by Caltech in providing such
assistance and cooperation as is requested pursuant to this Section 7.4. Licensee shall keep
Caltech reasonably informed of the progress of the legal action, and Caltech shall be
entitled to
be represented by counsel in connection with such legal action at its own expense. Licensee’s

- 12 -

 

reasonable and customary expenses for such action (including attorneys’ fees and expert fees) shall
be fully creditable against royalties owed to Caltech hereunder, provided that in no one year shall
such expenses to be credited against more than [***] of royalty payments to Caltech.
Any remaining expenses may be carried over and credited against royalties owed in future years.

     7.5 Licensee shall have the light to settle any claims, but only upon terms and conditions
that are reasonably acceptable to Caltech. Should Licensee elect to abandon such an action other
than pursuant to a settlement with the alleged infringer that is reasonably acceptable to Caltech,
Licensee shall give timely notice to Caltech who, if it so desires, may continue the action;
provided, however, that the sharing of expenses and any recovery in such suit shall be as agreed
upon between the parties.

     7.6 Any amounts paid to Licensee by third parties as the result of an action pursuant to this
Article 7 (such as in satisfaction of a judgment or pursuant to a settlement) shall first be
applied to reimbursement of the unreimbursed expenses (including attorneys’ fees and expert fees)
incurred by Licensee and then to the payment to Caltech of any royalties against which were
credited expenses of the action in accordance with Section 7.4. Any remainder shall be divided
between the parties as follows:

          (a) To the extent the amount recovered reflects lost profits, Licensee shall retain the
remainder, less the amount of any royalties that would have been due Caltech on sales of Licensed
Product lost by Licensee as a result of the infringement had Licensee made such sales, provided
that (i) Licensee shall in any event retain at least [***] of the remainder; and (ii)
Caltech shall receive an amount equal to the royalties it would have received if such sales had
been made by Licensee, provided such amount shall in no event exceed [***] of the
remainder; or

          (b) To the extent the amount recovered does not reflect lost profits, such amount shall be
shared by Caltech and Licensee pro rata according to the respective percentages of costs borne by
each in such action; provided, however, that in no event shall Caltech receive less than
twenty-five percent (25%) of such amount.

- 13 -

 

ARTICLE 8

BENEFITS OF LITIGATION,

EXPIRATION OR ABANDONMENT

     8.1 In a case where one or more patents or particular claims thereof within the
Licensed Patents expire, or are abandoned, or are declared invalid or unenforceable or
otherwise
construed by a court of last resort or by a lower court from whose decree no appeal is taken,
or
certiorari is not granted within the period allowed therefor, then the effect thereof
hereunder shall
be:

          (a) that such patents or particular claims shall, as of the date of expiration or abandonment
or final decision as the case may be, cease to be included within the Licensed Patents for the
purpose of this Agreement;

          (b) that such construction so placed upon the Licensed Patents by the court shall be followed
from and after the date of entry of the decision, and royalties shall
thereafter be payable by
Licensee only in accordance with such construction; and

          (c) In the event that Licensee challenges the validity of Licensed Patents, Licensee may not
cease paying royalties as of the date validity of the claims in issue are challenged, but rather
may cease paying royalties as to those claims only after a final adjudication of invalidity of
those claims.

     8.2 In the event that any of the contingencies provided for in Section 8.1 occurs,
Caltech agrees to renegotiate in good faith with Licensee a reasonable royalty rate under the
remaining Licensed Patents which are unexpired and in effect and under which Licensee desires to
retain a License.

ARTICLE 9

RECORDS, REPORTS AND PAYMENTS

     9.1 Licensee shall keep records and books of account in respect of all Licensed Products made
and sold by Licensee or its Affiliates under this Agreement and of royalties or other revenues
Licensee receives from Sublicensees other than Licensee’s Affiliates for the sale

- 14 -

 

of Licensed Products. Caltech shall have the right at its own cost, during Licensee’s business
hours, no more often than annually, to have an independent certified public accounting firm of
nationally recognized standing to examine such records and books. Licensee shall keep the same for
at least three (3) years after it pays Caltech the royalties due for such Licensed Products and
require Licensee’s Affiliates to do the same. The accounting firm shall disclose to Caltech only
whether or not the reports are correct and the amount of any
discrepancies. Caltech shall, and
shall cause its accounting firm to, not disclose to any third party any confidential information
learned through an examination of such records and books.

     9.2 Following
the first commercial sale of a Licensed Product, on or before the last day of
each February, May, August and November for so long as royalties are payable under this Agreement,
Licensee shall render to Caltech a report in writing, setting forth Net Sales and the number of
units of Licensed Products sold during the preceding calendar quarter by Licensee and its
Affiliates, and the royalties or other revenues received by Licensee from Net Sales of Licensed
Products made by Licensee’s Sublicensees other than Affiliates during the preceding calendar
quarter. Each such report shall also set forth an explanation of the calculation of the royalties
payable hereunder and be accompanied by payment of the royalties shown by said report to be due
Caltech. Notwithstanding foregoing, if (i) Caltech materially
breaches this Agreement, (ii) Licensee gives Caltech written
notice of the breach, and (iii) Caltech has not cured the breach
by the time a payment is due under this Section, then Licensee may
make the required payment into an interest bearing escrow account to
be released when the breach is cured, less any damages that may be
payable to License by virtue or Caltech’s breach. Royalty
reports which are not challenged by Caltech or amended by Licensee
within thirty-six (36) months after receipt by Caltech shall be
conclusively presumed correct and not subject to challenge, audit, or
amendment.

ARTICLE 10

CONFIDENTIALITY

     10.1 Except
as provided herein, each party shall maintain in confidence, and shall not use
for any purpose or disclose to any third party, information disclosed by the other party in
writing and marked “Confidential” or that is disclosed orally and confirmed in writing as

- 15 -

 

confidential within forty-five (45) days following such disclosure (collectively, “Confidential
Information”). Confidential Information shall not include any information that is; (i) already
known to the receiving party at the time of disclosure hereunder, (ii) now or hereafter becomes
publicly known other than through acts or omissions of the receiving party, (iii) disclosed to the
receiving party by a third party under no obligation of confidentiality to the disclosing party,
(iv) disclosed as required by securities or other applicable laws or pursuant to legal requirement,
or (v) disclosed to actual or prospective investors or corporate partners, or to a party’s
accountants, attorneys, and other professional advisors. All reports provided to Caltech by
Licensee pursuant to this Agreement shall be treated as confidential information of Licensee,
pursuant to this Section 10.1. The terms of this Agreement shall be treated as confidential
information of Licensee, pursuant to this Section 10.1.

     10.2 Notwithstanding the provisions of Section 10.1 above, Licensee may use or disclose
confidential information comprising the Licensed Patents and Technology to the extent necessary to
exercise its rights hereunder (including commercialization and/or sublicensing of the Licensed
Patents and Technology) or fulfill its obligations and/or duties hereunder and in filing for,
prosecuting or maintaining any proprietary rights, prosecuting or defending litigation, complying
with applicable governmental regulations and/or submitting information to tax or other
governmental authorities.

ARTICLE 11

PATENT PROSECUTION AND PATENT COSTS

     11.1 Licensee shall have the right to apply for, prosecute and maintain during the term of
this Agreement, the Licensed Patents. Caltech shall provide Licensee with timely disclosures
regarding Improvements and potential Improvements. The application filings, prosecution,
maintenance and payment of all fees and expenses, including legal fees, relating to such Licensed
Patents shall be the responsibility of Licensee, provided that Licensee shall pay for all
reasonable fees and expenses, including reasonable legal fees, incurred in such application
filings, prosecution and maintenance. Caltech shall provide Licensee with all information
necessary or useful for the filing and prosecution of such Licensed Patents and shall cooperate
fully with Licensee so that Licensee may establish and maintain such rights. Patent attorneys

- 16 -

 

chosen by Licensee shall handle all patent filings and prosecutions, on behalf of Caltech,
provided, however, Caltech shall be entitled to review and comment upon and approve all actions
undertaken in the prosecution of all patents and applications. Caltech shall provide any comments
or approvals hereunder promptly.

     11.2 In the event Licensee declines to apply for, prosecute or maintain any Licensed Patents,
Caltech shall have the right to pursue the same at Caltech’s expense and Licensee shall have no
rights under Caltech’s interest therein. If Licensee decides not to apply for, prosecute or
maintain any Licensed Patents, Licensee shall give sufficient and timely notice to Caltech so as to
permit Caltech to apply for, prosecute and maintain such Licensed
Patents. In such event, Licensee
shall provide Caltech with all information necessary or useful for the filing and prosecution of
such Licensed Patents and shall cooperate fully with Caltech so that Caltech may establish and
maintain such rights.

     11.3 Licensee shall reimburse Caltech for all reasonable out-of-pocket expenses incurred by
Caltech for the filing for, prosecution and maintenance of the Licensed Patents Rights. Such
expenses shall be reimbursed following receipt by Licensee from Caltech of (i) an invoice covering
such fees (including copies of invoices for legal fees describing the legal services performed in
reasonable detail) and (ii) reasonably satisfactory evidence that such fees were paid. Initially,
payments shall be made in six (6) equal quarterly installments due within ten days after the end
of the first six (6) full calendar quarters, effective twenty-four (24) months from the Effective
Date of this Agreement. Subsequent payments under this Section 11.3 shall be made to Caltech
within sixty (60) days following receipt by Licensee from Caltech of (i) an invoice covering such
fees (including copies of invoices for legal fees describing the legal services performed in
reasonable detail) and (ii) reasonably satisfactory evidence that such fees were paid. If Licensee
elects to no longer pay the expenses of a patent or patent application within the Licensed Patents
in any country, Licensee shall notify Caltech not less than thirty (30) days prior to such action.
In the event that Licensee elects not to pay such expenses the license granted to Licensee
hereunder shall terminate. [***] of patent expenses paid by Licensee in
conjunction with foreign patent costs shall be creditable against earned royalties due Caltech in
the respective territory covered by the patent or patents that are foreign filed.

- 17 -

 

ARTICLE 12

TERMINATION

     12.1 The term of this Agreement shall commence upon the Effective Date and shall terminate on
a country-by-country and Licensed Product by Licensed Product basis upon the expiration of the last
to expire Licensed Patent in such country. Caltech shall have the right to terminate this
Agreement, subsequent to and subject to the outcome of arbitration proceedings pursuant to Article
14, prior to the date it would otherwise expire pursuant to this Section 12.1 if Licensee fails to
make any payment due hereunder and Licensee continues to fail to make the payment, either to
Caltech directly or by placing any disputed amount into an interest bearing escrow account to be
released when the dispute is resolved, for a period of sixty (60) days after receiving written
notice from Caltech specifying Licensee’s failure. If this Agreement expires pursuant to the first
sentence of this Section 12.1, Licensee shall retain a nonexclusive, perpetual, royalty-free,
worldwide license, with the right to sublicense, under the Licensed Patents and Technology, to
research, develop, make, use, sell, offer for sale and import Licensed Products.

     12.2 If either party materially breaches this Agreement, the other party may elect to give the
bleaching party written notice describing the alleged breach. If the breaching party has not cured
such breach within sixty (60) days after receipt of such notice, the notifying party will be
entitled, in addition to any other rights it may have under this Agreement, to terminate this
Agreement effective immediately; provided, however, that if either party receives notification from
the other of a material breach and if the party alleged to be in default notifies the other party
in writing within thirty (30) days of receipt of such default notice that it disputes the asserted
default, the matter will be submitted to arbitration as provided in
Article 14 of this Agreement.
In such event, the nonbreaching party shall not have the right to terminate this Agreement until it
has been determined in such arbitration proceeding that the other party materially breached this
Agreement, and the breaching party fails to cure such breach within ninety (90) days after the
conclusion of such arbitration proceeding.

     12.3 Licensee shall have the right to terminate this Agreement either in its entirety or as to
any jurisdiction or any part of the Licensed Patents or Technology upon thirty (30) days

- 18 -

 

written notice. If Licensee does so, it shall submit all required reports and make all required
payments in accordance with Section 9.2

     12.4 In the event of any termination or expiration of the term of this Agreement, Licensee
shall have the right to use or sell Licensed Products on hand on the date of such termination or
expiration and to complete Licensed Products in the process of manufacture at the time of such
termination or expiration and use or sell the same, provided that Licensee shall submit the
applicable royalty report described in Section 9.2, along with the royalty payments required above
in accordance with Section 4.1 for sale of such Licensed Products, provided that the Licensed
Products are still covered by a Valid Claim following such termination or expiration.

     12.5 Termination of this Agreement for any reason shall not release any party hereto from any
liability which, at the time of such termination, has already accrued to the other party or which
is attributable to a period prior to such termination, nor preclude either party from pursuing any
rights and remedies it may have hereunder or at law or in equity which accrued or are based upon
any event occurring prior to such termination.

     12.6 Section 5.2 and Articles 10, 12, 14, and 16 of this Agreement shall survive
termination of this Agreement for any reason.

     12.7 If Licensee is acquired by or merges into a third party (i.e., Licensee is not a
surviving company in the merger), then Caltech may terminate its
obligations to disclose and grant licenses to Improvements by
providing notice to Licensee of that termination.  The
remainder of the Agreement and the licenses granted hereunder
(including prior licenses granted to Improvements) continues.

ARTICLE 13

WARRANTIES AND NEGATION OF

WARRANTIES, IMPLIED LICENSES AND AGENCY

     13.1 Caltech represents and warrants that (i) it owns all right, title and interest in and to
the Licensed Patents and Technology, (ii) it has the right to enter into this Agreement, (iii) it
has not granted and will not grant during the term of this Agreement rights in or to any Licensed

- 19 -

 

Patents or Technology that are inconsistent with the rights granted to Licensee herein, (iv) to
Caltech’s knowledge, there are no claims of third parties that would call into question the rights
of Caltech to grant to Licensee the rights contemplated hereunder; (v) to Caltech’s knowledge,
practice of the Licensed Patents will not infringe intellectual property rights of third parties;
(vi) except for the Licensed Patents, as of the effective date of the Agreement, to Caltech’s
belief and knowledge, Caltech does not own or control any patents or patent applications that would
dominate any practice of the Licensed Patents or Technology, and (vii) there are no threatened or
pending actions, suits, investigations, claims, or proceedings in any way relating to the Licensed
Patents or Technology.

     13.2 Nothing in this Agreement shall be construed as:

          (a) a representation or warranty of Caltech as to the validity or scope of
Licensed Patents or any claim thereof; or

          (b) an obligation to bring or prosecute actions or suits against third parties for
infringement.

          (c) conferring by implication, estoppel or otherwise, any license or rights under any
existing patents of Caltech other than Licensed Patents, regardless of whether such other patents
are dominant or subordinate to Licensed Patents. Notwithstanding the foregoing, and to the extent
legally permissible, Caltech hereby grants Licensee a right of first refusal as to such dominant
or subordinate patents, providing that a Caltech faculty member does not wish to personally
commercialize the technology embodied in such patents.

     13.3 CALTECH MAKES NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE, AND ASSUMES NO RESPONSIBILITIES WHATEVER WITH RESPECT TO THE USE, SALE, OR
OTHER DISPOSITION BY LICENSEE OF LICENSED PRODUCT(S).

     13.4 Caltech shall indemnify, defend and hold harmless Licensee from and against any and all
losses, damages, costs and expenses (including attorneys’ fees) arising out of a material breach
by Caltech of its representations and warranties (“Claims”), provided that (i) Caltech is notified
promptly of any Claims, (ii) Licensee has the sole right to control and defend or settle

- 20 -

 

any litigation within the scope of this indemnity, and (iii) all indemnified parties cooperate to
the extent necessary in the defense of any Claims.

ARTICLE 14

ARBITRATION

     14.1 Any dispute under this Agreement which is not settled by mutual consent shall be finally
settled by binding arbitration, conducted in accordance with the Commercial Arbitration Rules of
the American Arbitration Association by one (1) independent, neutral arbitrator appointed in
accordance with said rules. The arbitration shall be held in San Francisco, California. The
arbitrators shall determine what discovery shall be permitted, consistent with the goal of
limiting the cost and time that the parties must expend for discovery; provided the arbitrators
shall permit such discovery as they deem necessary to permit an equitable resolution of the
dispute. Any written evidence originally in a language other than English shall be submitted in
English translation accompanied by the original or a true copy thereof. Except as otherwise
expressly provided in this Agreement, the costs of the arbitration, including administrative and
arbitrator(s)’ fees, shall be shared equally by the parties and each party shall bear its own
costs and attorneys’ and witness’ fees incurred in
connection with the arbitration. A disputed
performance or suspended performances pending the resolution of the arbitration must be completed
within a reasonable time period following the final decision of the arbitrator(s). Any arbitration
subject to this Article shall be completed within one (1) year from the filing of notice of a
request for such arbitration. The arbitration proceedings and the decision shall not be made
public without the joint consent of the parties and each party shall maintain the confidentiality
of such proceedings and decision unless otherwise permitted by the other party. Any decision which
requires a monetary payment shall require such payment to be payable in United States dollars,
free of any tax or other deduction. The parties agree that the decision shall be the sole,
exclusive and binding remedy between them regarding any and all disputes, controversies, claims
and counterclaims presented to the arbitrators. Any award may be entered in a court of competent
jurisdiction for a judicial recognition of the decision and an order of enforcement.

- 21 -

 

ARTICLE 15

PRODUCT LIABILITY

     15.1 Licensee agrees that Caltech shall have no liability to Licensee or to any purchasers or
users of Licensed Products made or sold by Licensee for any claims, demands, losses, costs, or
damages suffered by Licensee, or purchasers or users of such Licensed Products, or any other party,
which may result from personal injury, death, or property damage related to the manufacture, use,
or sale of such Licensed Products (“Product Claims”). Licensee agrees to defend, indemnify, and
hold harmless Caltech, its trustees, officers, agents, and employees from any such Product Claims,
provided that (i) Licensee is notified promptly of any Product Claims, (ii) Licensee has the sole
right to control and defend or settle any litigation within the scope of this indemnity, (iii) all
indemnified parties cooperate in the defense of any Product Claims, and (iv) the Product Claims do
not involve or relate to a material breach by Caltech of its representations and warranties.

     15.2 At such time as Licensee begins to sell or distribute Licensed Products (other than for
the purpose of obtaining regulatory approvals), Licensee shall at its sole expense, procure and
maintain policies of comprehensive general liability insurance in amounts not less than [***] in annual aggregate and naming those
indemnified under Section 15.1 as
additional insureds. Such comprehensive general liability insurance shall provide (i) product
liability coverage and (ii) broad form contractual liability coverage for Licensee’s
indemnification under Section 15.1. In the event the aforesaid product liability coverage does not
provide for occurrence liability, Licensee shall maintain such comprehensive general liability
insurance for a reasonable period of not less than five (5) years after it has ceased commercial
distribution or use of any Licensed Product.

     15.3 Licensee shall provide Caltech with written evidence of Such insurance upon request of
Caltech. Licensee shall provide Caltech with notice at least fifteen (15) days prior to any
cancellation, non-renewal or material change in such insurance, to the extent Licensee
receives advance notice of such matters from its insurer. If Licensee does not obtain replacement
insurance providing comparable coverage within ninety (90) days following the date of such
cancellation, non-renewal or material change, Caltech shall have the right to terminate this

- 22 -

 

Agreement effective at the end of such ninety (90) day period without any additional waiting
period; provided that if Licensee uses reasonable efforts but is unable to obtain the required
insurance at commercially reasonable rates, Caltech shall not have the right to terminate this
Agreement, and Caltech instead shall cooperate with Licensee to either grant a waiver of Licensee’s
obligations under this Article or assist Licensee in identifying a carrier to provide such
insurance or in developing a program for self-insurance or other alternative measures.

ARTICLE 16

MISCELLANEOUS

     16.1 Licensee agrees that it shall not use the name of Caltech, or California Institute of
Technology, in any advertising or publicity material, or make any form of representation or
statement which would constitute an express or implied endorsement by Caltech of any Licensed
Product, and that it shall not authorize others to do so, without first having obtained written
approval from Caltech, except as may be required by governmental law, rule or regulation.

     16.2 Licensee agrees to mark the appropriate U.S. patent number or numbers on all Licensed
Products made or sold in the United States in accordance with all applicable governmental laws,
rules and regulations, and to require its Sublicensees to do the same.

     16.3 This Agreement sets forth the complete agreement of the parties concerning the subject
matter hereof. No claimed oral agreement in respect thereto shall be considered as any part
hereof. No waiver of or change in any of the terms hereof subsequent to the execution hereof
claimed to have been made by any representative of either party shall have any force or effect
unless in writing, signed by duly authorized representatives of the parties.

     16.4 This Agreement shall be binding upon and inure to the benefit of any successor or
assignee of Caltech. This Agreement is not assignable by Licensee without the prior written
consent of Caltech, except that Licensee may assign this Agreement without the prior written
consent of Caltech, to any Affiliate, or in connection with the sale or transfer of all or
substantially all the assets of Licensee relating to the Licensed Products or services utilizing
the methods within the Licensed Patents. Any permitted assignee shall succeed to all of the rights
and obligations of Licensee under this Agreement.

- 23 -

 

     16.5 This Agreement is subject in all respects to the laws and regulations of the United
States of America, including the Export Administration Act of 1979, as amended, and any regulations
thereunder.

     16.6 This Agreement shall be deemed to have been entered into in California and shall be
construed and enforced in accordance with California law.

     16.7 Any notice or communication required or permitted to be given or made under this
Agreement shall be addressed as follows:

	 	 	 	 	 
	 

	 	Caltech:
	 	Office of Technology Transfer
	 

	 	 	 	California Institute of Technology
	 

	 	 	 	1200 East California Boulevard (MC 210-85)
	 

	 	 	 	Pasadena, CA 91125
	 

	 	 	 	Fax No.: (626) 356-2486
	 
	 	 	 	 
	 

	 	Licensee:
	 	Fluidigm Corporation
	 

	 	 	 	7100 Shoreline Court
	 

	 	 	 	South San Francisco, CA 94080
	 

	 	 	 	Attn: President
	 

	 	 	 	Fax No: (650) 871-7195
	 

	 	 	 	Phone: (650) 266-6000

Either party may notify the other in writing of a change of address or fax number, in which event
any subsequent communication relative to this Agreement shall be sent to the last said notified
address or number, provided, however, that the parties shall deliver
all material notices under
this Agreement by registered mail or overnight delivery service. All notices and communications
relating to this Agreement shall be deemed to have been given when received.

     16.8 Nothing in this Agreement will impair Licensee’s right to independently acquire,
license, develop for itself, or have others develop for it, intellectual property and technology
performing similar functions as the Licensed Patents and Technology or to market and distribute
products other than Licensed Products based on such other intellectual property and technology.

     16.9 NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL,
OR INDIRECT DAMAGES ARISING OUT OF THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY.

- 24 -

 

     16.10 The relationship of Licensee and Caltech established by this Agreement is that of
independent contractors, Nothing in this Agreement shall be construed to create any other
relationship between Licensee and Caltech. Neither party shall have any right, power or
authority to assume, create or incur any expense, liability or obligation, express or implied,
on behalf of the other.

     16.11 Licensee agrees that a Licensed Product which embodies a patented invention or
is produced through the use thereof for sale in the United States shall be manufactured
substantially in the United States to the extent required by 35 U.S.C. Section 204.

     16.12 Neither party shall lose any rights hereunder or be liable to the other party for
damages or losses (except for payment obligations) on account of failure of performance by the
defaulting party if the failure is occasioned by war, strike, fire, Act of God, earthquake, flood,
lockout, embargo, governmental acts or orders or restrictions, failure of suppliers, or any other
reason where failure to perform is beyond reasonable control and not caused by the negligence or
intentional conduct or misconduct of the nonperforming party, and such party has exerted all
reasonable efforts to avoid or remedy such force majeure; provided, however, that in no event
shall a party be required to settle any labor dispute or disturbance.

     16.13 In the event that any provisions of this Agreement are determined to be invalid or
unenforceable by a court of competent jurisdiction, the remainder of the Agreement shall remain in
full force and effect without said provision. The parties shall in good faith negotiate a
substitute clause for any provision declared invalid or unenforceable, which shall most nearly
approximate the intent of the parties in entering this Agreement.

     16.14 This Agreement may be executed in two or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one
and the same instrument.

     16.15 The headings of the several Sections are inserted for convenience of reference only and
are not intended to be a part of or to affect the meaning or interpretation of this Agreement.

- 25 -

 

     16.16 Whenever provision is made in this Agreement for either party to secure the consent or
approval of the other, that consent or approval shall not unreasonably be withheld or delayed, and
whenever in this Agreement provisions are made for one party to object to or disapprove a matter,
such objection or disapproval shall not unreasonably be exercised.

     In Witness Whereof, the parties have caused this Agreement to be executed:

	 	 	 	 	 	 	 
	 	 	CALIFORNIA INSTITUTE OF TECHNOLOGY	 	 
	 	 	(Caltech)	 	 
	 
	 	 	 	 	 	 
	Date: 4/29/04

	 	By:

	 	/s/ Lawrence Gilbert
 

	 	 
	 
	 

	 	Name:

	 	Lawrence Gilbert
	 	 
	 
	 

	 	Title:
	 	Senior Director	 	 
	 

	 	 	 	Office of Technology Transfer	 	 
	 
	 	 	 	 	 	 
	Date: April 28, 2004	 	FLUIDIGM CORPORATION	 	 
	 	 	(Licensee)	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Gajus
Worthington 

	 	 
	 
	 

	 	Name:
	 	
Gajus Worthington
	 	 
	 
	 

	 	Title:
	 	President and CEO	 	 

- 26 -

 

Exhibit A

Licensed Patents

			
	Date: April 22, 2004
	 	Confidential

[***]

-27-

 

Exhibit A

Licensed Patents

[***]

-28-

 

Exhibit A

Licensed Patents

[***]

-29-

 

Exhibit A

Licensed Patents

[***]

-30-

 

     Exhibit A

Licensed Patents

[***]

-31- 

 

Exhibit A

Licensed Patents

[***]

-32-

 

Exhibit A

Licensed Patents

[***]

-33-

 

Exhibit A

Licensed Patents

[***]

-34-

 

Exhibit A

Licensed Patents

[***]

- 35 -

 

Exhibit A

Licensed Patents

[***]

- 36 -

 

Exhibit A

Licensed Patents

[***]

- 37 -

 

Exhibit A

Licensed Patents

[***]

- 38 -

 

Exhibit A

Licensed Patents

[***]

- 39 -

 

Exhibit A

Licensed Patents

[***]

- 40 -

 

     Exhibit A

Licensed Patents

[***]

- 41 -

 

Exhibit A

Licensed Patents

[***]

- 42 -

 

Exhibit A

Licensed Patents

[***]

-43-

 

Exhibit A

Licensed Patents

[***]

-44-exv10w4a

 

[***] Indicates
text has been omitted from this Exhibit pursuant to a confidential treatment
request and has been filed separately with the Securities and Exchange Commission.

Exhibit 10.4A

	 	 	 
	 

	 	2020.LICI.001.C
	 

	 	California Institute of Technology

ADDENDUM TO

SECOND AMENDED AND RESTATED LICENSE AGREEMENT

     THIS ADDENDUM TO SECOND AMENDED AND RESTATED LICENSE AGREEMENT (this “Addendum”) dated as
of March 29, 2007 (the “Addendum Date”), is entered into between CALIFORNIA INSTITUTE OF
TECHNOLOGY (“Caltech”), having an address at 1200 East California Boulevard, Pasadena,
California 91125, and FLUIDIGM CORPORATION (“Licensee”), having a principal place of business
at 7100 Shoreline Court, South San Francisco, California 94080, with respect to the following
facts:

      A. The parties entered into the Second Amended and Restated License
Agreement (the “Agreement”) effective May 1, 2000, with a second restatement date as
of May 1, 2004. All terms used, but not defined herein, shall have the respective
meanings set forth in the Agreement.

     B. On the terms and conditions of this Addendum, the parties desire to clarify
and modify certain provisions to the Agreement.

     NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants
set forth below, the parties agree as follows:

1. Licensed Patents and Improvements.

     1.1 The Agreement is amended by deleting Exhibit A to the Agreement and
by replacing it with Exhibit A to this Addendum.

     1.2 Caltech represents that it has disclosed to Licensee all Improvements
arising prior to the Addendum Date.

     1.3 The parties acknowledge that Exhibit A to this Addendum includes (a) all
Improvements disclosed by Caltech to Licensee prior to the Addendum Date, and elected
by Licensee to be included in the scope of the license grant by Caltech to Licensee under
the Agreement, and (b) all updates on all Licensed Patents as of the Addendum Date.
Caltech confirms that Licensee has taken all action on its part that is necessary for all
subject matter included in Exhibit A to this Addendum to be included in the scope of the
license grant by Caltech to Licensee under the Agreement.

2. Licensee Equity Interest and Improvement Periods.

     2.1 Notwithstanding anything to the contrary in Article 5 of the Agreement, the
Improvement Periods shall be those periods from June 1, 2003 through May 31, 2004, from June
1, 2004 through May 31, 2005, from [***]

1

 

     2.2 Notwithstanding anything to the contrary in Article 5 of the Agreement, (a) Licensee
shall issue to Caltech [***] [***] shares of common stock of Licensee, pursuant
to the terms of a reasonable and customary stock issuance agreement, and (b) the parties
acknowledge that the issuance of such shares (in addition to the shares issued by Licensee to
Caltech prior to the Second Restatement Date) shall be in full satisfaction of Licensee’s
obligations to issue shares or otherwise make payments to Caltech pursuant to the Agreement.

3. Royalty Reports.

     The parties acknowledge (a) that the royalty reports received by Caltech under Section 9.2 of
the Agreement prior to the Addendum Date are presumed correct and not subject to challenge, audit
or amendment, and (b) that the format of, and the methodology used by Licensee in preparing, the
royalty reports under Section 9.2 of the Agreement are mutually acceptable and in compliance with
the terms and conditions of the Agreement.

4. Patent Costs.

     Notwithstanding anything to the contrary in Article 11 of the Agreement, Licensee shall have
no obligation to reimburse Caltech for any costs or expenses incurred by Caltech in connection with
the Licensed Patents that have not been reimbursed by Licensee prior to the Addendum Date.

5. Further Assurances.

     Each party shall take such further actions, and execute such further documents and
instruments, as reasonably requested by the other party to effectuate the grant of licenses and
rights from Caltech to Licensee under the Agreement and otherwise to enable Licensee to enjoy the
full benefit thereof.

6. Miscellaneous.

     6.1 This Addendum shall be effective for all purposes as of the Addendum
Date. Except as otherwise expressly modified by this Addendum, the Agreement shall
remain in full force and effect in accordance with its terms.

     6.2 This Addendum shall be governed by, interpreted and construed in
accordance with the laws of the State of California, without regard to conflicts of law
principles.

     6.3 This Addendum may be executed in counterparts, each of which shall be
deemed to be an original and together shall be deemed to be one and the same document.

2

 

     IN WITNESS WHEREOF, the parties have caused this Addendum to be duly executed and delivered
effective as of the Addendum Date.

	 	 	 	 	 	 	 
	 	 	California Institute of Technology
	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Lawrence Gilbert	 	 
	 

	 	 	 	 	 	 
	 	 	(Signature)	 	 
	 
	 	 	 	 	 	 
	 	 	Lawrence Gilbert	 	 
	 	 	 	 	 
	 	 	(Printed Name)	 	 
	 
	 	 	 	 	 	 
	 	 	SR DR Tech Transfer	 	 
	 	 	 	 	 
	 	 	(Title)	 	 
	 
	 	 	 	 	 	 
	 	 	FLUIDIGM CORPORATION	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Gajus V. Worthington	 	 
	 

	 	 	 	 	 	 
	 	 	(Signature)	 	 
	 
	 	 	 	 	 	 
	 	 	Gajus V. Worthington
	 	 
	 	 	 	 	 
	 	 	(Printed Name)	 	 
	 
	 	 	 	 	 	 
	 	 	CEO
	 	 
	 	 	 	 	 
	 	 	(Title)	 	 

3

 

EXHIBIT A

[TO BE ATTACHED]

4

 

Appendix 1.7 Fluidigm Patent Family

US Cases

[ * * * ]

Page 1

 

Appendix 1.7 Fluidigm Patent Family

US Cases

[***]

Page 2

 

Appendix 1.7 Fluidigm Patent Family

US Cases

[***]

Page 3

 

Appendix 1.7 Fluidigm Patent Family

US Cases

[***]

Page 4

 

Appendix 1.7 Fluidigm Patent Family

US Cases

[***]

Page 5

 

Appendix 1.7 Fluidigm Patent Family

US Cases

[***]

Page 6

 

Appendix 1.7 Fluidigm Patent Family

US Cases

[***]

Page 7

 

Appendix 1.7 Fluidigm Patent Family

US Cases

[***]

Page 8

 

Appendix 1.7 Fluidigm Patent Family

US Cases

[***]

Page 9

 

Appendix 1.7 Fluidigm Patent Family

US Cases

[***]

Page 10

 

Appendix 1.7 Fluidigm Patent Family

US Cases

[***]

Page 11

 

Appendix 1.7 Fluidigm Patent Family

International Cases

[***]

 Page 1

 

Appendix 1.7 Fluidigm Patent Family

International Cases

[***]

 Page 2

 

Appendix 1.7 Fluidigm Patent Family

International Cases

[***]

 Page 3

 

Appendix 1.7 Fluidigm Patent Family

International Cases

[***]

 Page 4

 

Appendix 1.7 Fluidigm Patent Family

International Cases

[***]

 Page 5

 

Appendix 1.7 Fluidigm Patent Family

International Cases

[***]

 Page 6

 

Appendix 1.7 Fluidigm Patent Family

International Cases

[***]

 Page 7

 

Appendix 1.7
Fluidigm Patent
Family 

International Cases

[***]

Page 8

 

Appendix 1.7 Fluidigm
Patent Family

International Cases

[***]

Page 9

 

Appendix 1.7 Fluidigm Patent Family

International Cases

[***]

Page 10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00140-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00140-of-00352.parquet"}]]